missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human MIER1 (aa 428-512) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (89%), Rat (89%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-65607 (PA5-65607. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
The association of hMI-ER1 with Sp1 represents a novel mechanism for the negative regulation of Sp1 target promoters. Results demonstrate that alternate use of a facultative intron regulates the subcellular localization of hMI-ER1 proteins and this may have important implications for hMI-ER1 function in the regulation of transcription. Repressor activity is due to interaction and recruitment of a trichostatin A-sensitive histone deacetylase 1 (HDAC1).
Specifications
Specifications
| Accession Number | Q8N108 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 57708 |
| Name | Human MIER1 (aa 428-512) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 4933425I22Rik; 5830411K19Rik; early response 1; er1; hMI-ER1; Kiaa1610; mesoderm induction early response 1 homolog; mesoderm induction early response 1 homolog (Xenopus laevis; mesoderm induction early response 1, transcriptional regulator; mesoderm induction early response protein 1; MIER1; MI-ER1; MIER1 transcriptional regulator; RGD1562337; RP5-944N15.1) |
| Common Name | MIER1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction